` ESTA (Establishment Labs Holdings Inc) vs S&P 500 Comparison - Alpha Spread

ESTA
vs
S&P 500

Over the past 12 months, ESTA has significantly outperformed S&P 500, delivering a return of 49% compared to the S&P 500's 24% growth.

Stocks Performance
ESTA vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ESTA vs S&P 500

Loading
ESTA
S&P 500
Difference

Performance By Year
ESTA vs S&P 500

Loading
ESTA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Establishment Labs Holdings Inc vs Peers

S&P 500
ESTA
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Establishment Labs Holdings Inc
Glance View

Market Cap
1.3B USD
Industry
Health Care

Established at the intersection of innovation and aesthetics, Establishment Labs Holdings Inc. has carved a niche in the global medical technology landscape. Founded in 2004, this Costa Rica-based company has painstakingly built a reputation for its cutting-edge silicone breast implants and medical devices aimed at breast aesthetics and reconstruction. The company leverages advanced technology to deliver safer and more natural products, primarily through its signature Motiva Implants® brand. With its commitment to safety, quality, and innovation, Establishment Labs has successfully expanded into more than 80 countries, earning trust by catering to surgeons and patients with an ever-evolving portfolio of aesthetically driven solutions. Establishment Labs’ business model is intricately tied to the nuances of the cosmetic surgery industry, where product differentiation and regulatory compliance are paramount. The company invests heavily in research and development, focusing on creating next-generation breast implant technologies that prioritize patient safety and satisfaction. Revenue streams are driven by direct sales to plastic surgeons and healthcare providers, capitalizing on growing global demand for aesthetic procedures. Additionally, the company stays ahead of the competition by fostering strong relationships with medical professionals and continuously educating them about the benefits and capabilities of its innovative product offerings. This strategic alliance strengthens its market presence and aids consistent revenue growth, reinforcing its status as a forward-thinking leader in the medical aesthetics field.

ESTA Intrinsic Value
25.98 USD
Overvaluation 45%
Intrinsic Value
Price
Back to Top